Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Biofrontera (BFRI) over the last 5 years, with Q3 2025 value amounting to $236000.0.

  • Biofrontera's Share-based Compensation fell 1805.56% to $236000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $961000.0, marking a year-over-year increase of 137.13%. This contributed to the annual value of $1.0 million for FY2024, which is 248.8% down from last year.
  • Per Biofrontera's latest filing, its Share-based Compensation stood at $236000.0 for Q3 2025, which was down 1805.56% from $187000.0 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Share-based Compensation registered a high of $551000.0 during Q2 2022, and its lowest value of $129000.0 during Q4 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $249000.0 (2023), whereas its average is $294187.5.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 19689.92% in 2022, then plummeted by 5299.46% in 2023.
  • Over the past 5 years, Biofrontera's Share-based Compensation (Quarter) stood at $129000.0 in 2021, then soared by 196.9% to $383000.0 in 2022, then plummeted by 40.47% to $228000.0 in 2023, then soared by 31.14% to $299000.0 in 2024, then fell by 21.07% to $236000.0 in 2025.
  • Its Share-based Compensation stands at $236000.0 for Q3 2025, versus $187000.0 for Q2 2025 and $239000.0 for Q1 2025.